NEW YORK, July 19 (UPI) -- The journal Neuropsychopharmacology is the latest medical publication to say it would disclose researchers' ties to drug companies.
According to a report Wednesday in the Wall Street Journal, the medical journal said it would issue a correction to a published study because it had failed to disclose the relationships of eight of the study's nine authors to the company that makes a controversial anti-depression device.
The article published in Neuropsychopharmacology was about Cyberonic's implanted device that delivers electrical pulses to the patient's vagus nerve to treat depression.
However, the article omitted the fact that eight of the study's nine authors -- who called the Food and Drug Administration-approved device "promising and well-tolerated for treatment-resistant depression" -- worked as paid consultants to Cyberonics.
Earlier this month the Journal of the American Medical Association issued a correction to a study it published in February on the risks that women who stop taking anti-depressants during pregnancy could relapse into depression. The study article had failed to disclose that its seven authors had financial ties to the makers of anti-depressants, the newspaper said.
